Effect of CPAP on New Endothelial Dysfunction Marker, Endocan, in People With Obstructive Sleep Apnea.

Autor:	Altintas N; Department of Pulmonary, Sleep and Critical Care Medicine, School of Medicine, Namik Kemal University, Tekirdag, Turkey nejataltintas@gmail.com., Mutlu LC; Department of Pulmonary, Sleep and Critical Care Medicine, School of Medicine, Namik Kemal University, Tekirdag, Turkey., Akkoyun DC; Department of Cardiology, School of Medicine, Namik Kemal University, Tekirdag, Turkey., Aydin M; Department of Biochemistry, School of Medicine, Namik Kemal University, Tekirdag, Turkey., Bilir B; Department of Internal Medicine, School of Medicine, Namik Kemal University, Tekirdag, Turkey., Yilmaz A; Department of Biochemistry, School of Medicine, Namik Kemal University, Tekirdag, Turkey., Malhotra A; Department of Pulmonary, Sleep and Critical Care Medicine, San Diego, School of Medicine, University of California, San Diego, CA, USA.
Jazyk:	angličtina
Zdroj:	Angiology [Angiology] 2016 Apr; Vol. 67 (4), pp. 364-74. Date of Electronic Publication: 2015 Jun 15.
DOI:	10.1177/0003319715590558
Abstrakt:	Obstructive sleep apnea (OSA) is associated with increased cardiovascular (CV) morbidity and mortality. Endocan is a surrogate endothelial dysfunction marker that may be associated with CV risk factors. In this study, we tested whether serum endocan is a biomarker for OSA. Serum endocan levels were measured at baseline in 40 patients with OSA and 40 healthy controls and after 3 months of continuous positive airway pressure (CPAP) treatment in the patients with OSA. All participants were evaluated by full polysomnography. Flow-mediated dilatation (FMD) and carotid intima media thickness (cIMT) were measured in all participants. Endocan levels were significantly higher in patients with OSA than in healthy controls. After adjusting confounders, endocan was a good predictor of OSA. Endocan levels correlated with OSA severity (measured by the apnea-hypopnea index [AHI]). After 3 months of CPAP treatment, endocan levels significantly decreased. Endocan levels were significantly and independently correlated with cIMT and FMD after multiple adjustments. The cIMT and FMD also had significant and independent correlation with AHI. Endocan might be a useful marker for the predisposition of patients with OSA to premature vascular disease. (© The Author(s) 2015.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu